Paul Silva compensation by year
Vertex Pharmaceuticals Summary Compensation Table · the one fiscal year held| Component | FY2019 |
|---|---|
| Salary | $442,569 |
| Bonus | $0 |
| Stock awards | $1,895,084 |
| Option awards | $468,803 |
| Non-equity incentive | $378,000 |
| Pension and deferred compensation | $0 |
| All other | $13,401 |
| Total | $3,197,857 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vertex Pharmaceuticals Inc DEF 14A filed April 28, 2020, accession 0001308179-20-000229, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Vertex Pharmaceuticals Inc filed document, accession 0001308179-20-000229. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2020.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 5,000 | $1,094,750 | — |
| RSU | 3,160 | $691,882 | — |
| RSU | 2,917 | $638,677 | — |
| RSU | 2,814 | $616,125 | — |
| RSU | 2,813 | $615,906 | — |
| PSU | 2,110 | $461,985 | — |
| RSU | 2,108 | $461,547 | — |
| RSU | 2,107 | $461,328 | — |
| RSU | 1,459 | $319,448 | — |
| PSU | 1,459 | $319,448 | — |
| Option | 1,290 | — | $91.05 |
| Option | 5,503 | — | $155.57 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Vertex Pharmaceuticals Inc's FY2019 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.
Vertex Pharmaceuticals’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Jeffrey Leiden | Executive Chairman (CEO and President through March 31, 2020) | $18,789,985 |
| Stuart Arbuckle | EVP & Chief Commercial Officer | $6,859,533 |
| Reshma Kewalramani | CEO and President (EVP & Chief Medical Officer through March 31, 2020) | $6,816,936 |
| Amit Sachdev | EVP & Chief Patient Officer | $6,197,053 |
| Michael Parini | EVP & Chief Administrative, Legal and Business Development Officer | $6,039,497 |
| Charles Wagner | EVP & Chief Financial Officer | $3,487,213 |
| Paul Silva · this page | SVP & Corporate Controller (Interim CFO for a portion of 2019) | $3,197,857 |
| Ian Smith | Former EVP & Chief Operating Officer and Former Interim Chief Financial Officer | $1,451,840 |
The full Vertex Pharmaceuticals compensation record
free company briefThis page is one person within Vertex Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Vertex Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vertex Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.